Pfizer Unveils ATLAS®, An Interactive, User-Friendly Website That Provides Global Antibiotic Resistance Surveillance Data Ac...
April 21 2017 - 7:36AM
Business Wire
ATLAS® Is Designed To Help Physicians Select
Appropriate Antibiotics For Their Patients And Responds To The Need
For Mobile Resources At The Point Of Care
ATLAS Can Also Help Inform Global Health
Strategies To Mitigate The Threat Of Antimicrobial Resistance
(AMR)
Pfizer Inc. today announced the launch of the company’s
Antimicrobial Testing Leadership and Surveillance (ATLAS) website,
which is designed to provide physicians and the global health
community with easy access to critical data on the efficacy of
various antibiotic treatments and emerging resistance patterns
across more than 60 countries. Understanding evolving bacterial
resistance patterns is a key element in managing the rise of
antimicrobial resistance. To that end, ATLAS can not only help
physicians select the most appropriate treatment choices for their
patients, but also enable global health authorities to develop
data-driven antimicrobial resistance mitigation strategies. Pfizer
will formally unveil ATLAS on April 22nd at the annual meeting of
the European Congress of Clinical Microbiology and Infectious
Disease (ECCMID) in Vienna.
This Smart News Release features multimedia.
View the full release here:
http://www.businesswire.com/news/home/20170421005363/en/
ATLAS can be accessed through
atlas-surveillance.com and can be downloaded on mobile phones
through the App Store (Graphic: Business Wire)
Mobile devices and applications provide many benefits for
healthcare professionals including increased access to point of
care tools, which have been shown to support better clinical
decision making and improved patient outcomes. In response to this
need, Pfizer also offers ATLAS as a mobile application to enable
rapid access to important resistance information at the point of
patient care.
ATLAS offers an interactive platform that enables physicians to
evaluate data, conduct analyses, and export tables and figures that
include parameters such as pathogen, region, specimen source and in
vitro susceptibility data. The ATLAS database is updated every six
months with new resistance data from healthcare institutions in
more than 60 countries as these become available. ATLAS can be
accessed by visiting: www.atlas-surveillance.com.
“An important aspect for physicians when treating patients is
knowledge; knowledge of where certain resistant bacterial
infections tend to occur and knowledge of which antibiotics remain
effective against them,” said Dr. Freda Lewis-Hall, Chief Medical
Officer of Pfizer Inc. “ATLAS underscores our continued commitment
to providing patients and physicians with meaningful resources that
can help ensure appropriate utilization of antibiotics and improve
infection prevention and control.”
About Antimicrobial Resistance
(AMR)
The World Health Organization (WHO) characterizes antimicrobial
resistance as one of the biggest threats to global health, that can
affect anyone at any age in any country, threatening our ability to
treat serious infections and provide standard medical procedures.
Gram-negative bacteria, the cause of many healthcare-associated
infections (HAIs), have become increasingly resistant to many
available antibiotic treatments. These infections are associated
with increased patient mortality and cost of care. At present,
approximately 700,000 deaths per year are attributed to
antimicrobial resistance globally, with an increase to 10 million
predicted by 2050 if no action is taken to address this issue.
About Pfizer’s Commitment to
Antimicrobial Resistance:
Today, Pfizer is the leading global provider of anti-infective
medicines in the industry, offering patients access to a diverse
portfolio of more than 80 products. Pfizer recognizes the serious
public health threat associated with AMR and has taken significant
steps to address this issue. In early 2016, Pfizer was a signatory
of the Declaration on Combating Antimicrobial Resistance (AMR), a
global call-to-action drafted and signed by more than 100 companies
and 13 trade associations encouraging greater industry and
government collaboration to address the issue of antimicrobial
resistance. As a follow-up to the AMR Declaration, Pfizer and 13
industry partners unveiled the “Industry Roadmap to Combat
Antimicrobial Resistance,” a comprehensive plan of action, that
lays out four key commitments we pledge to deliver by 2020. For
more information on Pfizer’s commitment to AMR, please click
here.
About Pfizer
Anti-Infectives
Since its pioneering work on penicillin in the 1940s, Pfizer has
been actively engaged in the research and development of innovative
medicines, policies and educational programs to address the
evolving needs of patients and physicians in the area of infectious
diseases.
For more than 30 years, Pfizer has been a leader in developing
and implementing innovative public-private partnerships designed to
address unmet medical needs and global public health issues. Today,
our patient assistance programs expand access to potentially
lifesaving medicines and provide educational resources that empower
patients and physicians in the fight against infectious
disease.
Pfizer Inc.: Working together
for a healthier world®
At Pfizer, we apply science and our global resources to bring
therapies to people that extend and significantly improve their
lives. We strive to set the standard for quality, safety and value
in the discovery, development and manufacture of health care
products. Our global portfolio includes medicines and vaccines as
well as many of the world's best-known consumer health care
products. Every day, Pfizer colleagues work across developed and
emerging markets to advance wellness, prevention, treatments and
cures that challenge the most feared diseases of our time.
Consistent with our responsibility as one of the world's premier
innovative biopharmaceutical companies, we collaborate with health
care providers, governments and local communities to support and
expand access to reliable, affordable health care around the world.
For more than 150 years, we have worked to make a difference for
all who rely on us. We routinely post information that may be
important to investors on our website at www.pfizer.com. In
addition, to learn more, please visit us on www.pfizer.com and
follow us on Twitter at @Pfizer and @PfizerNews, LinkedIn, YouTube
and like us on Facebook at Facebook.com/Pfizer.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170421005363/en/
Pfizer Inc.Media:Allyanna Anglim,
212-733-4945Allyanna.Anglim@pfizer.comorInvestors:Ryan Crowe,
212-733-8160Ryan.Crowe@pfizer.com
Pfizer (NYSE:PFE)
Historical Stock Chart
From Mar 2024 to Apr 2024
Pfizer (NYSE:PFE)
Historical Stock Chart
From Apr 2023 to Apr 2024